Daiwa Securities Group Inc. Has $7.13 Million Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Daiwa Securities Group Inc. lifted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 10.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 91,195 shares of the company’s stock after buying an additional 8,834 shares during the period. Daiwa Securities Group Inc.’s holdings in GE HealthCare Technologies were worth $7,130,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GEHC. Ashton Thomas Securities LLC bought a new stake in GE HealthCare Technologies in the 3rd quarter valued at approximately $26,000. Capital Performance Advisors LLP bought a new stake in shares of GE HealthCare Technologies in the third quarter worth $26,000. Darwin Wealth Management LLC acquired a new position in GE HealthCare Technologies during the third quarter worth $31,000. Continuum Advisory LLC grew its position in GE HealthCare Technologies by 101.8% in the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares in the last quarter. Finally, Bank of Jackson Hole Trust acquired a new stake in GE HealthCare Technologies in the 4th quarter valued at $32,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $100.00 in a research note on Tuesday. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Citigroup upped their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Finally, Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Trading Up 0.3 %

GEHC stock opened at $85.59 on Wednesday. The stock has a market cap of $39.14 billion, a price-to-earnings ratio of 19.77, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The company has a fifty day moving average price of $87.06 and a two-hundred day moving average price of $86.17. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Equities analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.